Peltier Skye, Kellum Angela, Brewer Janet, Duncan Alexander, Cooper David L, Saad Hossam
Center for Bleeding and Clotting Disorders, University of Minnesota Medical Center - Fairview, Minneapolis, MN, USA.
Louisiana Center for Bleeding and Clotting Disorders, Tulane University, New Orleans, LA, USA.
J Blood Med. 2020 Sep 11;11:297-303. doi: 10.2147/JBM.S259909. eCollection 2020.
Congenital factor VII (FVII) deficiency is a rare bleeding disorder of variable phenotype with predominantly mucocutaneous bleeding. The aim of this study was to identify the burden of FVII deficiency on patients and caregivers through a better understanding of the management and psychosocial impact of this disease.
A rare disease specialty recruiter from Comprehensive Health Education Services recruited participants for this online survey, which was conducted from January 31 to March 12, 2019. A moderator-assisted questionnaire was used to collect data on demographics, diagnosis, treatment, and psychosocial impact.
Of the 45 respondents (25 patients and 20 caregivers), the majority were female (56%). Respondents reported a wide variety of initial bleeding symptoms, including bruising (58%), epistaxis (56%), and menorrhagia (36% of females). Because symptoms varied between individuals and were not always severe, diagnosis was often delayed. Mean time to obtain a diagnosis was 6.5 years and mean age at first diagnosis was 12.9 years. One-quarter (24%) of the respondents reported more than 100 bleeds of any severity over the previous year. When treating bleeds, 44% of patients reported using antifibrinolytics, and 42% reported using recombinant activated factor VII. Almost 31% of respondents reported missing schooldays as children, and 16% reported losing or resigning from a job in adulthood as a direct result of their disease. Notably, 29% of caregivers and 10% of their partners had also experienced issues with employment. Forty percent of respondents reported not participating in contact sports during childhood, and 22% continued to avoid contact sports in adulthood.
Overall, FVII deficiency has a substantial psychosocial impact, but most patients are satisfied with their disease management and are optimistic about their future. Patients desire additional educational, social, and financial support.
先天性凝血因子 VII(FVII)缺乏症是一种罕见的出血性疾病,其表型各异,主要表现为黏膜皮肤出血。本研究的目的是通过更好地了解该疾病的管理及社会心理影响,来确定 FVII 缺乏症对患者及照料者的负担。
综合健康教育服务机构的一名罕见病专业招募人员为这项在线调查招募参与者,该调查于2019年1月31日至3月12日进行。采用主持人辅助的问卷收集有关人口统计学、诊断、治疗及社会心理影响的数据。
在45名受访者(25名患者和20名照料者)中,大多数为女性(56%)。受访者报告了各种各样的初始出血症状,包括瘀伤(58%)、鼻出血(56%)和月经过多(女性中的36%)。由于个体症状各不相同且并不总是很严重,诊断常常延迟。获得诊断的平均时间为6.5年,首次诊断时的平均年龄为12.9岁。四分之一(24%)的受访者报告在过去一年中有超过100次任何严重程度的出血。在治疗出血时,44%的患者报告使用抗纤溶药物,42%的患者报告使用重组活化凝血因子 VII。近31%的受访者报告童年时缺课,16%的受访者报告成年后因疾病直接导致失去工作或辞职。值得注意的是,29%的照料者及其10%的伴侣也遇到过就业问题。40%的受访者报告童年时不参加接触性运动,22%的受访者成年后仍避免接触性运动。
总体而言,FVII 缺乏症具有重大的社会心理影响,但大多数患者对其疾病管理感到满意,并对未来持乐观态度。患者希望获得更多的教育、社会和经济支持。